DUBLIN--(BUSINESS WIRE)--The "Epiomic Epidemiology Series: Retinal Vein Occlusion Forecast in 18 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.
Retinal vein occlusion (RVO) is a common vascular disorder of the retina and the second-most common cause of vision loss worldwide after diabetic retinopathy. Its classification and pathogenesis have not yet been fully established, and even though a range of therapeutic approaches to RVO are available, sequelae of the disorder may still lead to a significant degree of vision loss by various mechanisms.
This report provides the current prevalent population for RVO across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the author's, RVO subtypes, several features of RVO patients, as well as the main comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of RVO include:
- Cardiovascular diseases (mainly hypertension)
- Diabetes mellitus
Key Topics Covered:
- Cause Of The Disease
- Risk Factors & Prevention
- Diagnosis Of The Disease
- Variation By Geography/Ethnicity
- Disease Prognosis & Clinical Course
- Key Comorbid Conditions / Features Associated With The Disease
- Methodology For Quantification Of Patient Numbers
- Top-Line Prevalence For Retinal Vein Occlusion
- Features Of Retinal Vein Occlusion Patients
- Central Rvo
- Branch Rvo
- Abbreviations Used In The Report
- Reports & Publications
- Online Epidemiology Databases
- Online Pharmaceutical Pricing Database
For more information about this report visit https://www.researchandmarkets.com/research/gmzbhv/epiomic?w=4